Seelos Therapeutics Inc (SEEL)

NASDAQ
2.330
-0.120(-4.90%)
After Hours
2.360
+0.030(+1.288%)
- Real-time Data
  • Volume:
    1,502,154
  • Bid/Ask:
    2.330/2.350
  • Day's Range:
    2.320 - 2.440

SEEL Overview

Prev. Close
2.45
Day's Range
2.32-2.44
Revenue
-
Open
2.43
52 wk Range
0.56-6.6
EPS
-0.57
Volume
1,502,154
Market Cap
237.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,522,197
P/E Ratio
-
Beta
3.06
1-Year Change
109.91%
Shares Outstanding
101,826,087
Next Earnings Date
Aug 13, 2021
What is your sentiment on Seelos Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Seelos Therapeutics Inc News

Seelos Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Seelos Therapeutics Inc Company Profile

Seelos Therapeutics Inc Company Profile

Employees
9

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Read More
  • hi Fellow investors- do you know why SEEL is falling daily. pls share your views
    0
    • hi Fellow investors- any particular reason this is falling everyday: SEEL
      0
      • An ATH today.
        1
        • soon 8- 9$
          1
          • I want to invest in this company but stock price looks extended.. any one with suggestions is it buy?...
            1
            • I bought last year at 0.55c .. no way its a buy, at this price
              1
            • Jean BaubineGood job dude. But now that it has viable fda prospects I could see it going to 8.50
              1
            • Well done. Although now that it has viable fda prospects I could see it going to 8.50
              0
          • Keeps going up in overtime.....⤴️
            0
            • thougths?
              0
              • Target for the stock is set at $15 I'm thinking that's what I want.
                0
              • Saw that!
                0
            • I dont see why this cant be $7 soon
              0
              • will it rise
                0
                • It has risen!☝️🆙🔝↗️
                  0
              • DIrector Raj Mehra acquired 1,150,000 shares @ $4.31 on 3/15/2021. It should definitely go higher today. IMHO today's price target is > $5.
                1
                • Today's price target is $5
                  0
                  • I believe it
                    0
                    • Next week we'll see 7+
                      1
                      • I dont think so....
                        0
                    • good choice!
                      0
                      • Lucky to stay above $4 by eod
                        0
                        • Bc the short manipulation? I think so too. I’m fine if they all go bankrupt here shortly.
                          0
                      • I want to see this at $200
                        0
                        • i would love to see it at that range
                          0
                      • New price point being reported at $14. Give it a google.
                        0
                        • Nice!
                          0
                      • I'm sitting on this one for a few years. See you guys in 2023
                        0
                        • why?
                          0
                      • next catalyst?
                        0
                        • slightly lower on low volume. In line with minor Nasdaq drop
                          0
                          • What is happening with this stock?
                            0
                            • I dont know but I would like to see it above $6 asap
                              0
                          • up up up
                            0
                            • any news on this stock???
                              1
                              • included to ETF
                                0
                              • lots. go to Google
                                0
                              • lots. go to Google
                                0
                            • Anyone on this? Take Profit?
                              1
                              • Ron Storeryour TP?
                                0
                            • Anyone on this ??
                              0
                              • I was waching this today when it was 88c i wait abit to see what is doing it went up to 1.05 so i decide to buy it cuz it was keep going up so i bought it at 1.07 sudenly came down to 96c but now looks like going up
                                0
                              • I'm watching it. no idea yet prediction is at 8
                                0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.